All In Biotech

BLA 020898 · Genzyme

Thyrogen

Thyrotropin Alfa · Injection · Thyroid Stimulating Hormone

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 12, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Nov 30, 1998

Approved uses

5

Original approval plus efficacy supplements

Registered trials

86

18 Phase 3, 8 recruiting

FAERS reports

1,038

353 serious, 23 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 24, 2023.

THYROGEN ® is a thyroid stimulating hormone indicated for: Adjunctive Diagnostic Tool for Well-Differentiated Thyroid Cancer: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. ( 1.1 ) Limitations of Use : THYROGEN-stimulated Tg levels are generally lower than, and do not correlate with Tg levels after thyroid hormone withdrawal. Even when THYROGEN-Tg testing is performed in combination with radioiodine imaging, there remains a risk of missing a diagnosis of thyroid cancer or underestimating the extent of the disease. Anti-Tg Antibodies may confound the Tg assay and render Tg levels uninterpretable. Adjunct for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer: Use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer. ( 1.2 ) Limitations of Use : The effect of THYROGEN on thyroid cancer recurrence greater than 5 years post-remnant ablation has not been evaluated. 1.1 Adjunctive Diagnostic Tool for Well-Differentiated Thyroid Cancer THYROGEN ® is indicated for use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. Limitations of Use : THYROGEN-stimulated Tg levels are generally lower than, and do not correlate with, Tg levels after thyroid hormone withdrawal [see Clinical Studies (14.1) ] . Even when THYROGEN-stimulated Tg...

Mechanism: Thyrotropin (TSH) is a pituitary hormone that stimulates the thyroid gland to produce thyroid hormone. Binding of thyrotropin alfa to TSH receptors on normal thyroid epithelial cells or on well-differentiated thyroid cancer tissue stimulates iodine uptake and organification, and synthesis and secretion of thyroglobulin (Tg), triiodothyronine (T3) and thyroxine (T4). The effect of thyroid stimulating hormone activation of thyroid cells is to increase uptake of radioiodine to allow scan detection or radioiodine killing of thyroid cells. TSH activation also leads to the release of thyroglobulin...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 12, 2020 Supplement 65 · Efficacy OrphanLetterLabel
  • Mar 21, 2014 Supplement 54 · Efficacy LetterLabel
  • Dec 14, 2007 Supplement 29 · Efficacy · priority review LabelLetter
  • Jan 24, 2006 Supplement 31 · Efficacy LabelLetter
  • Nov 30, 1998 Original approval · Type 1 - New Molecular Entity · priority review OtherReviewLetter
1 products under this application
  • THYROGEN · THYROTROPIN ALFA 1.1MG/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Thyrotropin Alfa" as an intervention, any sponsor and status, largest first.

All 86 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea130
  • headache83
  • fatigue82
  • off label use81
  • vomiting53
  • malaise43
  • dizziness41
  • pain41
  • drug ineffective38
  • blood thyroid stimulating hormone decreased28
  • asthenia26
  • pyrexia26

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200415
20057
200614
200719
200813
200917
201024
201113
201220
201366
201461
201559
201666
201761
201840
201965
202049
202174
202276
202370
2024102
202561
202646

Recalls

1 FDA enforcement reports for this application.

  • Feb 16, 2016 · Class II · Terminated

    Presence of Particulate Matter: Glass particles found in the product after reconstitution.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Thyrogen (Thyrotropin Alfa)

2024 spending

$315K

Beneficiaries

70

74 claims

Per beneficiary

$4,503

$2,101.46 per unit

View as table
YearSpending
2020$205,598
2021$259,926
2022$352,321
2023$398,120
2024$315,219

Part B: Thyrogen (Thyrotropin Alfa) · HCPCS J3240

2024 spending

$12.3M

Beneficiaries

2,930

4,912 claims

Per beneficiary

$4,215

2024 ASP limit $2,045.68 per unit

View as table
YearSpending
2020$10,698,002
2021$11,030,313
2022$11,964,457
2023$12,139,009
2024$12,348,775

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.